- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Celgene Corp (CELG)
| Open: | 121.5000 | Day's Range: | 120.5500 - 124.9700 | Volume: | 2,370,746 |
|---|---|---|---|---|---|
| Previous Close: | 123.6400 | 52wk Range: | 58.5300 - 131.8190 | 1-Yr Rtn: | +76.86% |
Key Statistics for CELG
| Current P/E Ratio (ttm) | 29.9497 |
|---|---|
| Estimated P/E(12/2013) | 21.6305 |
| Relative P/E vs. SPX | 1.8590 |
| Earnings Per Share (USD) (ttm) | 4.1282 |
| Est. EPS (USD) (12/2013) | 5.7160 |
| Est. PEG Ratio | 0.8996 |
| Market Cap (M USD) | 51,573.02 |
| Shares Outstanding (M) | 417.12 |
| 30 Day Average Volume | 3,353,792 |
| Price/Book (mrq) | 9.3068 |
| Price/Sale (ttm) | 9.2339 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/25/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for CELG
Company Profile & Key Executives for CELG
Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
| Robert J HuginChairman/President/CEO | Jacqualyn A FouseExec VP/CFO |
| Perry A KarsenExec VP/COO | Thomas O DanielExec VP/Pres:Research |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
CELG News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page